Cardiff Oncology Stock Today
| CRDF Stock | USD 4.03 0.06 1.51% |
Performance4 of 100
| Odds Of DistressLess than 8
|
Cardiff Oncology is trading at 4.03 as of the 1st of February 2025. This is a 1.51 percent increase since the beginning of the trading day. The stock's lowest day price was 3.97. Cardiff Oncology has only a 8 % chance of going through financial distress over the next few years but had a somewhat insignificant performance during the last 90 days. The performance scores are derived for the period starting the 5th of August 2024 and ending today, the 1st of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of July 2004 | Category Healthcare | Classification Health Care |
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Cardiff Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 66.52 M outstanding shares of which 9.48 M shares are currently shorted by private and institutional investors with about 5.73 trading days to cover. More on Cardiff Oncology
Moving against Cardiff Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Cardiff Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsCardiff Oncology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cardiff Oncology's financial leverage. It provides some insight into what part of Cardiff Oncology's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Cardiff Oncology (CRDF) is traded on NASDAQ Exchange in USA. It is located in 11055 Flintkote Avenue, San Diego, CA, United States, 92121 and employs 31 people. Cardiff Oncology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 264.1 M. Cardiff Oncology conducts business under Biotechnology sector and is part of Health Care industry. The entity has 66.52 M outstanding shares of which 9.48 M shares are currently shorted by private and institutional investors with about 5.73 trading days to cover.
Cardiff Oncology currently holds about 122.01 M in cash with (30.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.82.
Check Cardiff Oncology Probability Of Bankruptcy
Ownership AllocationCardiff Oncology holds a total of 66.52 Million outstanding shares. Cardiff Oncology shows 5.62 percent of its outstanding shares held by insiders and 27.49 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cardiff Ownership Details
Cardiff Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Blair William & Co | 2024-09-30 | 247.1 K | |
| Gsa Capital Partners Llp | 2024-09-30 | 186.7 K | |
| Two Sigma Investments Llc | 2024-09-30 | 184.6 K | |
| Bank Of New York Mellon Corp | 2024-09-30 | 171.1 K | |
| Millennium Management Llc | 2024-09-30 | 152.7 K | |
| Marshall Wace Asset Management Ltd | 2024-09-30 | 143 K | |
| Avestar Capital, Llc | 2024-09-30 | 140.5 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 121.3 K | |
| Xtx Topco Ltd | 2024-09-30 | 120.4 K | |
| Blackrock Inc | 2024-09-30 | 2.7 M | |
| Vanguard Group Inc | 2024-09-30 | 2.2 M |
Cardiff Oncology Historical Income Statement
Cardiff Stock Against Markets
Cardiff Oncology Corporate Management
| James Levine | Chief Officer | Profile | |
| Mark Erlander | CEO Director | Profile | |
| Vicki Kelemen | Chief Officer | Profile | |
| Tod Smeal | Chief Officer | Profile | |
| Brigitte Lindsay | Senior Finance | Profile | |
| MD FACP | Chief Officer | Profile | |
| Charles RPh | Senior Affairs | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiff Oncology. If investors know Cardiff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiff Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share | Quarterly Revenue Growth 0.17 | Return On Assets | Return On Equity |
The market value of Cardiff Oncology is measured differently than its book value, which is the value of Cardiff that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiff Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cardiff Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiff Oncology's market value can be influenced by many factors that don't directly affect Cardiff Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiff Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiff Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiff Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.